<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05116293</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00011644</org_study_id>
    <nct_id>NCT05116293</nct_id>
  </id_info>
  <brief_title>Effect of Testosterone Treatment on Drug Metabolism and Transport</brief_title>
  <official_title>Effect of Gender-Affirming Testosterone Therapy on Drug Metabolism, Transport, and Gut Microbiota</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will evaluate the effect of gender-affirming testosterone treatment on how other&#xD;
      medications are processed by the body.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gender-affirming hormone therapy may include testosterone, a hormone that the body creates&#xD;
      and uses naturally. Testosterone is prepared as a medication that patients may take to&#xD;
      increase hormone levels. Changes in testosterone concentrations in the body may affect how&#xD;
      the body processes other medicines. The purpose of this study is to find out how testosterone&#xD;
      therapy affects a single tracer dose of approved medicines in the blood (midazolam, digoxin,&#xD;
      and acetaminophen) and to confirm testosterone treatment does not affect natural bacterial in&#xD;
      the gut.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>midazolam AUC ratio (treatment/control)</measure>
    <time_frame>0-48 hours</time_frame>
    <description>ratio of the area under of the plasma concentration time curve (AUC) of midazolam in the presence to absence of gender-affirming testosterone treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>midazolam Cmax ratio (treatment/control)</measure>
    <time_frame>0-48 hours</time_frame>
    <description>ratio of the maximum plasma concentration (Cmax) of midazolam in the presence to absence of gender-affirming testosterone treatment</description>
  </secondary_outcome>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Transgender Persons</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam oral solution</intervention_name>
    <description>Oral syrup</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin Oral Tablet</intervention_name>
    <description>Oral tablet</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen Oral Tablet</intervention_name>
    <description>Oral tablet</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Transgender adults planning to take testosterone treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Self-identified trans* adult at least 18 years of age.&#xD;
&#xD;
          -  Not taking testosterone treatment currently.&#xD;
&#xD;
          -  Planning to start testosterone treatment through care provider for gender-affirming&#xD;
             medical care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling/unable to return for project follow-up visits.&#xD;
&#xD;
          -  Unwilling/unable to provide written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Self-identify as transgender or trans nonbinary</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren Cirrincione, MPH,Pharm D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Cirrincione, MPH, PharmD</last_name>
    <phone>650-353-7782</phone>
    <email>lc10@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Cirrincione, (she/her)</last_name>
      <email>lc10@uw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Lauren Cirrincione</investigator_full_name>
    <investigator_title>Assistant Professor, Pharmacy</investigator_title>
  </responsible_party>
  <keyword>Testosterone Treatment</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

